From: Using highly variable warfarin dosing to identify patients at risk for adverse events
Demographics | Cases (%) | Controls (%) | P-value |
---|---|---|---|
Age 75 or Older | 50 | 42 | 0.20* |
Female | 45 | 32 | 0.02* |
Nonwhite Race | 11 | 6 | 0.10* |
Hypertension | 48 | 47 | 0.99* |
Diabetes | 21 | 21 | 0.99* |
Coronary Artery Disease | 39 | 34 | 0.53* |
Follow up time | 10.9 months | 11.5 months | < 0.001†|
# INR/month | 2.3 | 1.2 | < 0.001†|
Indication: | Â | Â | 0.26* |
Atrial Fibrillation | 67 | 58 | Â |
VTE | 11 | 13 | Â |
Valvular Heart disease | 6 | 5 | Â |
Other | 16 | 24 | Â |